{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T19:05:47Z","timestamp":1776366347479,"version":"3.51.2"},"reference-count":42,"publisher":"Elsevier BV","issue":"3-4","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.ejps.2013.07.008","type":"journal-article","created":{"date-parts":[[2013,7,24]],"date-time":"2013-07-24T23:17:58Z","timestamp":1374707878000},"page":"282-289","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling"],"prefix":"10.1016","volume":"50","author":[{"given":"Marija","family":"Jovanovi\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dragoslav","family":"Soki\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iztok","family":"Grabnar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toma\u017e","family":"Vovk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milica","family":"Prostran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarina","family":"Vu\u010di\u0107evi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Branislava","family":"Miljkovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2013.07.008_b0005","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00007691-200406000-00005","article-title":"Topiramate serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and monitoring implications","volume":"26","author":"Adin","year":"2004","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ejps.2013.07.008_b0010","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jchromb.2006.12.016","article-title":"A novel high sensitivity HPLC assay for topiramate, using 4-chloro-7-nitrobenzofurazan as pre-column fluorescence derivatizing agent","volume":"850","author":"Bahrami","year":"2007","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.ejps.2013.07.008_b0015","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2165\/00003088-200544040-00005","article-title":"Topiramate pharmacokinetics in children and adults with epilepsy: a case-matched comparison based on therapeutic drug monitoring data","volume":"44","author":"Battino","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2013.07.008_b0020","unstructured":"Bauer, R.J., 2011. NONMEM Users Guides. Introduction to NONMEM 7.2.0. Icon Development Solutions. Ellicott City, Maryland, USA."},{"key":"10.1016\/j.ejps.2013.07.008_b0025","unstructured":"Beal, S.L., Sheiner, L.B., Boeckmann, A.J., 1989\u20132011. NONMEM Users Guides. Icon Development Solutions, Ellicott City, Maryland, USA."},{"key":"10.1016\/j.ejps.2013.07.008_b0030","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2165\/00003088-200443120-00001","article-title":"Pharmacokinetic interactions of topiramate","volume":"43","author":"Bialer","year":"2004","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2013.07.008_b0035","series-title":"Pharmacokinetic\u2013Pharmacodynamic Modeling and Simulation","author":"Bonate","year":"2006"},{"key":"10.1016\/j.ejps.2013.07.008_b0040","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.eplepsyres.2010.12.004","article-title":"Topiramate pharmacokinetics in infants and young children: contribution of population analysis","volume":"93","author":"Bouillon-Pichault","year":"2011","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.ejps.2013.07.008_b0045","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.0013-9580.2005.55204.x","article-title":"Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine","volume":"46","author":"Britzi","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejps.2013.07.008_b0050","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/00007691-200206000-00002","article-title":"Topiramate therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs","volume":"24","author":"Contin","year":"2002","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ejps.2013.07.008_b0055","series-title":"The Treatment of Epilepsy","first-page":"673","article-title":"Antiepileptic drugs: topiramate","author":"Cooss","year":"2009"},{"key":"10.1016\/j.ejps.2013.07.008_b0065","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/j.1552-4604.1996.tb04754.x","article-title":"Single-dose pharmacokinetics and effect of food on the bioavailability of topiramate, a novel antiepileptic drug","volume":"36","author":"Doose","year":"1996","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2013.07.008_b0060","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1046\/j.1528-1157.2003.64402.x","article-title":"Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and combination therapy in epilepsy patients","volume":"44","author":"Doose","year":"2003","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejps.2013.07.008_b0070","unstructured":"Drug Interaction Checker. Cerner Multum, I., Denver, CO., <http:\/\/www.drugs.com\/drug_interactions.html> (accessed 12.12)."},{"key":"10.1016\/j.ejps.2013.07.008_b0075","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1345\/aph.1D374","article-title":"Population pharmacokinetics. I: background, concepts, and models","volume":"38","author":"Ette","year":"2004","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ejps.2013.07.008_b0080","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1097\/00007691-200312000-00008","article-title":"Influence of dosage, age, and co-medication on plasma topiramate concentrations in children and adults with severe epilepsy and preliminary observations on correlations with clinical response","volume":"25","author":"Ferrari","year":"2003","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ejps.2013.07.008_b0085","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1111\/j.1528-1167.2010.02598.x","article-title":"Pharmacokinetic-pharmacodynamic assessment of topiramate dosing regimens for children with epilepsy 2 to <10years of age","volume":"51","author":"Girgis","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejps.2013.07.008_b0090","unstructured":"Guidance for Industry: Bioanalytical Method Validation, May 2001. US FDA."},{"key":"10.1016\/j.ejps.2013.07.008_b0095","first-page":"647","article-title":"Drug therapy in patients with chronic renal failure","volume":"107","author":"Hartmann","year":"2010","journal-title":"Dtsch. Arztebl. Int."},{"key":"10.1016\/j.ejps.2013.07.008_b0100","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1007\/s11095-007-9361-x","article-title":"Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method","volume":"24","author":"Hooker","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2013.07.008_b0110","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1586\/ern.09.136","article-title":"Drug interaction involving the new second- and third- generation antiepileptic drugs","volume":"10","author":"Johannessen Landmark","year":"2010","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.ejps.2013.07.008_b0105","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/FTD.0b013e31825ee389","article-title":"Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedication","volume":"34","author":"Johannessen Landmark","year":"2012","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ejps.2013.07.008_b0115","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1023\/A:1011970125687","article-title":"Automated covariate model building within NONMEM","volume":"15","author":"Jonsson","year":"1998","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2013.07.008_b0120","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/sj.clpt.6100241","article-title":"Diagnosing model diagnostics","volume":"82","author":"Karlsson","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2013.07.008_b0125","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ejps.2010.06.016","article-title":"A population pharmacokinetic evaluation of the influence of CYP2D6 genotype on risperidone metabolism in patients with acute episode of schizophrenia","volume":"41","author":"Locatelli","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2013.07.008_b0130","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1007\/s11095-009-9961-8","article-title":"The antiepileptic drug topiramate is a substrate for human P-glycoprotein but not multidrug resistance proteins","volume":"26","author":"Luna-Tortos","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2013.07.008_b0135","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.2165\/00003495-200767150-00008","article-title":"Topiramate: a review of its use in the treatment of epilepsy","volume":"67","author":"Lyseng-Williamson","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.ejps.2013.07.008_b0140","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/00007691-200206000-00007","article-title":"Serum concentrations of topiramate in patients with epilepsy: influence of dose, age, and comedication","volume":"24","author":"May","year":"2002","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ejps.2013.07.008_b0145","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1111\/j.1528-1167.2005.06805.x","article-title":"A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy","volume":"46","author":"Mimrod","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejps.2013.07.008_b0150","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0169-2607(98)00098-4","article-title":"A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models","volume":"59","author":"Parke","year":"1999","journal-title":"Comput. Methods Programs Biomed."},{"issue":"Suppl. 9","key":"10.1016\/j.ejps.2013.07.008_b0155","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1528-1167.2005.00326.x","article-title":"Properties of antiepileptic drugs in the treatment of idiopathic generalized epilepsies","volume":"46","author":"Patsalos","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejps.2013.07.008_b0160","series-title":"The Epilepsy Prescriber\u2019s Guide to Antiepileptic Drugs","author":"Patsalos","year":"2010"},{"key":"10.1016\/j.ejps.2013.07.008_b0165","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1006\/phrs.1997.0124","article-title":"A pharmacological and clinical review on topiramate, a new antiepileptic drug","volume":"35","author":"Perucca","year":"1997","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejps.2013.07.008_b0170","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10928-007-9081-1","article-title":"Extensions to the visual predictive check to facilitate model performance evaluation","volume":"35","author":"Post","year":"2008","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.ejps.2013.07.008_b0175","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/S0149-2918(97)80006-9","article-title":"Topiramate: a review of preclinical, pharmacokinetic, and clinical data","volume":"19","author":"Rosenfeld","year":"1997","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejps.2013.07.008_b0180","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/j.1528-1157.1997.tb01124.x","article-title":"Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy","volume":"38","author":"Rosenfeld","year":"1997","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejps.2013.07.008_b0185","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/j.1528-1157.1996.tb00651.x","article-title":"Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy","volume":"37","author":"Sachdeo","year":"1996","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejps.2013.07.008_b0190","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.pharmthera.2006.07.005","article-title":"Novel anticonvulsant drugs","volume":"113","author":"Stefan","year":"2007","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2013.07.008_b0195","unstructured":"Summary of Product characteristic for Topamax Tablets and Sprinkle Capsules, Last updated on the eMC: 28\/11\/2012. <http:\/\/www.medicines.org.uk\/emc\/medicine\/6768#PHARMACOKINETIC_PROPS>."},{"key":"10.1016\/j.ejps.2013.07.008_b0200","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1365-2125.2006.02756.x","article-title":"Population pharmacokinetics of darbepoetin alfa in haemodialysis and peritoneal dialysis patients after intravenous administration","volume":"63","author":"Takama","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2013.07.008_b0205","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1248\/bpb.33.1176","article-title":"A nonlinear mixed effects modelling analysis of topiramate pharmacokinetics in patients with epilepsy","volume":"33","author":"Vovk","year":"2010","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejps.2013.07.008_b0210","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.ejps.2009.09.017","article-title":"The influence of drug-drug interaction and patients\u2019 characteristics on valproic acid\u2019s clearance in adults with epilepsy using nonlinear mixed effects modeling","volume":"38","author":"Vucicevic","year":"2009","journal-title":"Eur. J. Pharm. Sci."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098713002625?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098713002625?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:44:45Z","timestamp":1760528685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098713002625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":42,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0928098713002625"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2013.07.008","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2013.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}